Phase 1/2 Trial to Test aTyr Pharma’s ATYR1923 in Pulmonary Sarcoidosis Patients
aTyr Pharma, which developing therapies to modulate immune pathways involved in lung diseases, has announced an upcoming Phase 1b/2a study to test their lead therapy ATYR1923 in patients with pulmonary sarcoidosis. ATYR1923 is an immunomodulatory molecule that’s able to bind to the Neuropilin-2 (NRP-2) receptor protein, part of…